News
Nuvalent buy delivers new cancer approval for GSK
GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.
Oncology
Sponsored
Establishing ctDNA as a validated primary surrogate endpoint
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
News
Repligen builds in cell therapy with $1.5bn BioLife takeover
Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Oncology
Early diagnosis means little without timely treatment
Early diagnosis only changes outcomes if it is followed by timely treatment.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
